The Drugs Controller General of India gave permission for conducting Phase-1 clinical trial for antisera obtained by injecting horses with inactivated SARS-CoV-2. The antisera have been developed by the Indian Council of Medical Research (ICMR) in collaboration with a Hyderabad-based bio-pharmaceutical firm and are believed to be a potential treatment for COVID-19. Antisera is blood serum high in antibodies against specific antigens having prophylactic or therapeutic potential when injected into infected persons. Some of the key highlights of the study are: Ten healthy horses were immunized with inactivated SARS-CoV-2.
Plasma samples of horses were tested after 21 days of immunization. Plasma samples revealed the presence of SARS-CoV-2 specific IgG antibodies as detected in ELISA and PRNT with neutralizing capacity. Potential for developing highly purified F(ab')2 from equines against…
